Zavation Medical Products, LLC
Katie Motley
Design Engineer
220 Lakeland Parkway
Flowood, Mississippi 39232

September 9, 2019

Re: K191354
Trade/Device Name: Ti3Z Cervical Interbody System
Regulation Number: 21 CFR 888.3080
Regulation Name: Intervertebral Body Fusion Device
Regulatory Class: Class II
Product Code: ODP
Dated: July 31, 2019
Received: August 1, 2019

Dear Katie Motley:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

for
Melissa Hall
Assistant Director
DHT6B: Division of Spinal Devices
OHT6: Office of Orthopedic Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120
Expiration Date: 06/30/2020
See PRA Statement below.

510(k) Number *(if known)*
K191354

Device Name
Ti 3Z Cervical Interbody System

Indications for Use *(Describe)*

When used as a cervical intervertebral body fusion device, the Zavation Ti 3Z Cervical Interbody System implants are indicated for spinal fusion procedures to be used with autogenous bone graft in skeletally mature patients. The cervical IBF implants are intended for use at one level in the cervical spine, from C2 to T1, for the treatment of cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies). The cervical device is intended to be used in patients who have had six weeks of non-operative treatment.

For all the above indications the Zavation Ti 3Z Cervical Interbody implants are intended to be used with supplemental internal fixation appropriate for the implanted level, including Zavation Cervical Plate System.

Type of Use *(Select one or both, as applicable)*

☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510K Summary

Date:	August 1, 2019
Submitter:	Zavation Medical Products, LLC 220 Lakeland Pkwy Flowood, MS 39232 Phone: 601-919-1119 Fax: 800-447-1302
Contact person:	Katie Motley
Type of 510(k) submission:	Traditional
Trade name:	Ti 3Z Cervical Interbody System
Common name:	Intervertebral Body Fusion Device
Classification regulation:	21 CFR 888.3080 Intervertebral body fusion device
Device classification:	Class II
Classification Panel:	Orthopedic
Product code:	ODP

Device Description:
The Zavation Ti 3Z Cervical Interbody implants offer a variety of heights, widths and lengths in the CIF configuration. The implants are additively manufactured from medical grade Titanium Ti64ELI powder by way of laser sintering.

The Zavation Ti 3Z Cervical Interbody implants are available in a range of sizes, as well as parallel and lordotic angled implants, to accommodate variations in patients' anatomy. The internal body of the implants have a porous structure while the external edges of the implants have a solid, roughened surface designed to engage with the vertebral body end plates. Both porous and solid aspects of each implant are printed simultaneously.

Purpose of 510K:
New Interbody Device.

Indications for Use:
When used as a cervical intervertebral body fusion device, the Zavation Ti 3Z Cervical Interbody System implants are indicated for spinal fusion procedures to be used with autogenous bone graft in skeletally mature patients. The cervical IBF implants are intended for use at one level in the cervical spine, from C2 to T1, for the treatment of cervical disc disease (defined as neck pain of discogenic origin with

degeneration of the disc confirmed by history and radiographic studies). The cervical device is intended to be used in patients who have had six weeks of non-operative treatment.

For all the above indications the Zavation Ti 3Z Cervical Interbody implants are intended to be used with supplemental internal fixation appropriate for the implanted level, including Zavation Cervical Plate System.

Materials:
The devices are manufactured from medical grade Titanium Ti64ELI (ASTM F3001-14).

Predicate Device:
Primary -Zavation IBF System, Zavation LLC (K181246)
Additional – LDR Spine Cervical Interbody Fusion System (K091088)
Additional – K2M CASCADIA Interbody System (K172941)
Reference Predicate – Zavation Ti 3Z Interbody System (K180076)

Technological Characteristics:
The Zavation Ti 3Z Cervical Interbody System possesses similar technological characteristics as the predicates. These include: basic design (material, rectangular shape with bulleted nose, and graft windows for packing autogenous bone); sizes (similar heights, widths, lengths, and lordotic angles); and intended use (as described above).

Performance Data:
Mechanical test results demonstrated that the Zavation Ti 3Z Interbody System is substantially equivalent to the predicate devices. Testing was performed in accordance with:

- ASTM F2077, Test Methods for Intervertebral Body Fusion Devices
    - Static Axial Compression
    - Dynamic Axial Compression
    - Static Torsion
    - Dynamic Torsion
    - Subsidence
    - Expulsion

Process Validation test results demonstrate that the Zavation Ti 3Z Interbody System (K180076) is free from any possible contaminants and the cleaning process is adequate for implants to be provided sterile. The Zavation Ti 3Z Cervical Interbody System manufacturing, post processing, cleaning, sterilization, and packaging is identical to that of Zavation Ti 3Z Interbody System (K180076). Testing was performed in accordance with:

- ASTM F 2847-10, Standard Practice for Reporting Assessment of Residues on Single Use Implants
    - Gravimetric Analysis, ASTM F 2459-12
    - Cytotoxicity, ISO 10993-5: 2009
    - Total Organic Carbon
    - Limulus Amebocyte Lysate (LAL) (Endotoxin)

Basis for Substantial Equivalence:
The Zavation Ti 3Z Cervical Interbody devices are similar to the predicate systems with respect to technical characteristics, performance, and intended use. The information provided within this premarket notification supports substantial equivalence of the subject spacers to the predicate devices and is therefore safe and effective for its intended use.